Kurosaki, T.; Suzuki, S.; Yonesaka, K.; Kawanaka, Y.; Takehara, T.; Teramura, T.; Sakai, K.; Nishio, K.; Hayashi, H.
Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression. Int. J. Mol. Sci. 2025, 26, 10515.
https://doi.org/10.3390/ijms262110515
AMA Style
Kurosaki T, Suzuki S, Yonesaka K, Kawanaka Y, Takehara T, Teramura T, Sakai K, Nishio K, Hayashi H.
Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression. International Journal of Molecular Sciences. 2025; 26(21):10515.
https://doi.org/10.3390/ijms262110515
Chicago/Turabian Style
Kurosaki, Takashi, Shinichiro Suzuki, Kimio Yonesaka, Yusuke Kawanaka, Toshiyuki Takehara, Takeshi Teramura, Kazuko Sakai, Kazuto Nishio, and Hidetoshi Hayashi.
2025. "Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression" International Journal of Molecular Sciences 26, no. 21: 10515.
https://doi.org/10.3390/ijms262110515
APA Style
Kurosaki, T., Suzuki, S., Yonesaka, K., Kawanaka, Y., Takehara, T., Teramura, T., Sakai, K., Nishio, K., & Hayashi, H.
(2025). Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression. International Journal of Molecular Sciences, 26(21), 10515.
https://doi.org/10.3390/ijms262110515
